STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELVN
  4. [Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Enliven Therapeutics (ELVN) CMO trades 5,000 shares and exercises 5,000 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins reported both stock sales and an option exercise in the company’s shares. On May 18, 2026, she sold a total of 5,000 shares of Common Stock in open-market transactions at prices including $39.5340, $40.2473 and $41.2052 per share.

On the same date, she exercised a stock option to acquire 5,000 shares of Common Stock at an exercise price of $2.4800 per share. Following these transactions, she directly owned 25,000 shares of Common Stock and held 126,268 stock options exercisable at $2.4800 per share, expiring on June 17, 2031. The filing notes that the option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.

Positive

  • None.

Negative

  • None.
Insider Collins Helen Louise
Role CHIEF MEDICAL OFFICER
Sold 5,000 shs ($199K)
Approx. gross sale proceeds $199K
Approx. exercise cost $12K
Approx. pre-tax spread $187K
Type Security Shares Price Value
Exercise Stock Option (right to buy) 5,000 $0.00 $0.00
Exercise Common Stock 5,000 $2.48 $12K
Sale Common Stock 3,475 $39.534 $137K
Sale Common Stock 1,302 $40.2473 $52K
Sale Common Stock 223 $41.2052 $9K
Holdings After Transaction: Stock Option (right to buy) — 126,268 shares (Direct); Common Stock — 25,000 shares (Direct)
Footnotes (7)
  1. F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
  2. F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  3. F3. This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. F4. This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. F5. This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  6. F6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  7. F7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Shares sold 5,000 shares Total Common Stock sold on May 18, 2026
Sale prices $39.5340, $40.2473, $41.2052 per share Weighted-average prices for reported open-market sales
Options exercised 5,000 shares at $2.4800/share Stock option exercise into Common Stock on May 18, 2026
Shares held after 25,000 shares Direct Common Stock ownership following reported transactions
Options remaining 126,268 options at $2.4800/share Stock options outstanding after the exercise
Option expiration June 17, 2031 Expiration date of the reported stock option grant
Net share change 5,000 net shares sold NetBuySellShares from transaction summary
Rule 10b5-1 trading plan regulatory
"The option exercise and sales ... were effected pursuant to a Rule 10b5-1 trading plan adopted ..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units (RSUs) financial
"Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
fully vested and exercisable financial
"All of the shares subject to this option are fully vested and exercisable as of the date hereof."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Enliven Therapeutics (ELVN) CMO Helen Collins trade in this Form 4?
Helen Collins reported selling 5,000 shares of Enliven Therapeutics Common Stock and exercising options for 5,000 shares. The trades occurred on May 18, 2026, and involved open-market sales plus a stock option exercise at a $2.4800 per-share exercise price.

At what prices did Helen Collins sell ELVN shares in this Form 4 filing?
Helen Collins’ reported open-market sales occurred at weighted-average prices of $39.5340, $40.2473 and $41.2052 per share. Footnotes state each sale was executed through multiple trades within price ranges, with full trade details available upon request from the issuer or regulators.

How many Enliven Therapeutics shares does Helen Collins hold after these transactions?
After the reported trades, Helen Collins directly owns 25,000 shares of Enliven Therapeutics Common Stock. In addition, she holds 126,268 stock options with a $2.4800 exercise price, providing potential future equity exposure if she chooses to exercise additional options before expiration.

What stock options did Helen Collins exercise in the ELVN Form 4?
She exercised a stock option covering 5,000 shares of Enliven Therapeutics Common Stock at a $2.4800 exercise price. Footnotes note that all shares subject to this option were fully vested and exercisable, and the option carries an expiration date of June 17, 2031.

Was the Enliven Therapeutics (ELVN) insider trading done under a Rule 10b5-1 plan?
Yes. A footnote states the option exercise and related sales were effected under a Rule 10b5-1 trading plan. The plan was adopted on October 19, 2025, indicating these transactions were pre-arranged rather than discretionary trades based solely on short-term market conditions.

Does this ELVN Form 4 include any information on restricted stock units (RSUs)?
Yes. Footnotes explain that certain reported securities are restricted stock units, each RSU representing a contingent right to receive one share of Enliven Therapeutics Common Stock. RSUs typically vest over time or upon meeting conditions, then settle into actual shares for the reporting person.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Collins Helen Louise
(Last)(First)(Middle)
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
(Street)
BOULDER COLORADO 80301
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF MEDICAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026M(1)5,000A$2.4830,000(2)D
Common Stock05/18/2026S(1)3,475D$39.534(3)26,525(2)D
Common Stock05/18/2026S(1)1,302D$40.2473(4)25,223(2)D
Common Stock05/18/2026S(1)223D$41.2052(5)25,000(6)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.4805/18/2026M(1)5,000 (7)06/17/2031Common Stock5,000$0126,268D
Explanation of Responses:
1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
5. This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
6. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
7. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
/s/ Ben Hohl, by power of attorney05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR